Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2018 09:46 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Triple Therapy Data Presentations at the Upcoming 60th American Society of Hematology Annual Meeting and Exposition

Investor and Analyst Event to be Held on Sunday December 2, 2018 at 7:30 PM PT at the Marriot Gaslamp San Diego with Presentations by Leading Clinical Investigators NEW YORK, Nov. 01, 2018 (GLOBE...
October 11, 2018 11:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the 34th Congress of ECTRIMS

Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial ECTRIMS data review conference call to be held today, October 11, 2018, 19:30 CEST/1:30pm ET NEW YORK, Oct. 11,...
October 08, 2018 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Highlights Schedule of Events at the Upcoming 34th Congress of ECTRIMS

Final ublituximab phase 2 Multiple Sclerosis data to be featured in an oral presentation, Thursday, October 11, 2018, 16:51-17:03 CEST ECTRIMS data review conference call to be held Thursday, October...
September 28, 2018 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. to Present at Upcoming Investor Conferences

NEW YORK, Sept. 28, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its participation at two upcoming investor conferences. Michael S. Weiss, the Company’s Executive...
September 26, 2018 08:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Accepted for Oral Presentation at the Upcoming 34th Congress of ECTRIMS

Annualized Relapse Rate (ARR) of 0.07 observed for all patients Complete (100%) elimination of T1 Gd-enhancing lesions at week 24 and maintained at week 48 NEW YORK, Sept. 26, 2018 (GLOBE...
September 25, 2018 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial

NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics (NASDAQ: TGTX) today announced that the independent Data Safety Monitoring Board (DSMB) for the UNITY-CLL Phase 3 trial met to review...
August 07, 2018 16:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2018 Financial Results

NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2018 and recent company developments. ...
August 07, 2018 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Completion of Target Enrollment in the ULTIMATE Phase 3 Trials in Multiple Sclerosis

NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that target enrollment in the ULTIMATE I and II Phase 3 trials has been achieved. ULTIMATE I and II...
August 06, 2018 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2018 Financial Results and Business Update

NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held tomorrow, Tuesday, August 7, 2018 at 4:30pm ET to discuss...
June 20, 2018 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody

NEW YORK, June 20, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) and Novimmune SA, today announced that the companies have entered into an exclusive global agreement to collaborate on...